 |
|
- Main page
- News
- RJLabM Credits
- Archive
- Instructions for authors
- Online applications
- Editorial
- About us
-
Links
- Committee on Publication Ethics (COPE)
- International Committee of Medical Journal Editors
- Acta Marisiensis Seria Medica
- Bacteriologia, Virusologia, Parazitologia, Epidemiologia
- Biochemia Medica
- Clinical Chemistry and Laboratory Medicine
- Clinical Chemistry
- Clinica Chimica Acta
- Documenta Haematologica
- Romanian Journal of Morphology and Embryology
- Biostatistics and web search strategies (Romanian)
- How to spot a statistical problem
- Statistical Analyses and Methods in the Published Literature
ISSN online: 2284-5623
ISSN-L: 1841-6624
Rejection rate (2020): 75%
Journal Metrics
Impact Factor 0.5 Five Year Impact Factor 0.5 JCI 0.12
Log in
Concept, Design & Programming
Dr. Adrian Man
Research article Wharton’s jelly-mesenchymal stem cells alleviate atopic dermatitis by regulating TXNIP/NLRP3 and HDAC3/TGF‐β1 signaling pathway in mice ZhengPing Wu, JiaYi Cai, Ning Li, Di Han, Hong Liu, XinWen Mai, SenYu Chen, ManYu Liao, Peng Zhang, Chi-Ming Liu
Correspondence should be addressed to: Chi-Ming Liu
Abstract: Background: Atopic dermatitis (AD) is a chronic immune and inflammatory dermatologic disease. Preclinical and clinical studies have indicated that stem cell transplantation is considered an alternative treatment option for ameliorating the symptoms of AD. However, the molecular mechanisms by which stem cells treat AD remain unclear. This study aimed to evaluate the therapeutic effects of Wharton’s jelly mesenchymal stem cells in a 2,4-dinitrofluorobenzene (DNFB)-induced mouse model of AD. Methods: Human Wharton’s jelly-mesenchymal stem cells (hWJ-MSCs) were subcutaneously injected into mice receiving DNFB on day 7 (DNFB-MSC 7 group) and days 7 and 16 (DNFB-MSC 7, 16 group). Results: hWJ-MSCs improved the symptoms of AD and lowered the clinical skin score. After treatment with hWJ-MSCs, the skin thickness of the epidermis was reduced in AD mice. hWJ-MSCs decreased the serum concentration of IgE. Mechanically, hWJ-MSCs inhibited the expression of proteins associated with the NLRP3 inflammasome, such as NLRP3, ASC/TMS1, TXNIP, and caspase-1. Furthermore, hWJ-MSCs regulated the expression of TGF-β1 and histone deacetylase 3 (HDAC3) proteins. Conclusions: Taking these results together, treatment with hWJ-MSCs improved the clinical symptoms by regulating TXNIP/NLRP3 and HDAC3/TGF‐β1 signaling cascade. Keywords: atopic dermatitis, HDAC3, mesenchymal stem cells, NLRP3, TGF-β
Received: 8.5.2025 |
|||||
|
Download full text PDF (4587 KB) |
||||
|
Wu Z, Cai J, Li N, Han D, Liu H, Mai X, et al. Wharton’s jelly-mesenchymal stem cells alleviate atopic dermatitis by regulating TXNIP/NLRP3 and HDAC3/TGF‐β1 signaling pathway in mice. Rev Romana Med Lab. 2025;33(4):241-50. DOI:10.2478/rrlm-2025-0028
|
|||||